{"pmid":32500660,"title":"Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.","text":["Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: a single-center real-life experience.","Dermatol Ther","Rossi, Mariateresa","Rovati, Chiara","Arisi, Mariachiara","Soglia, Simone","Calzavara-Pinton, Piergiacomo","32500660"],"journal":"Dermatol Ther","authors":["Rossi, Mariateresa","Rovati, Chiara","Arisi, Mariachiara","Soglia, Simone","Calzavara-Pinton, Piergiacomo"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32500660","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/dth.13765","keywords":["covid-19","atopic dermatitis","dupilumab"],"topics":["Prevention"],"weight":1,"_version_":1668890966464921600,"score":9.490897,"similar":[{"pmid":32330323,"title":"Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","text":["Safety of dupilumab in severe atopic dermatitis and infection of Covid-19: two case reports.","Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.","J Eur Acad Dermatol Venereol","Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S","32330323"],"abstract":["Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). It shows good efficacy with a rapid response and good safety with few side effects. In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients."],"journal":"J Eur Acad Dermatol Venereol","authors":["Ferrucci, S","Romagnuolo, M","Angileri, L","Berti, E","Tavecchio, S"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330323","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16527","keywords":["covid-19","atopic dermatitis","dupilumab","interstitial pneumonia"],"e_drugs":["dupilumab"],"topics":["Case Report"],"weight":1,"_version_":1666138494748065792,"score":194.65819},{"pmid":32339362,"title":"No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","text":["No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1).","J Eur Acad Dermatol Venereol","Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P","32339362"],"abstract":["Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339362","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16552","keywords":["covid-19","dupilumab","atopic dermatitis"],"locations":["Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138494311858176,"score":182.80453},{"pmid":32419563,"title":"Safety of dupilumab in atopic patients during COVID-19 outbreak.","text":["Safety of dupilumab in atopic patients during COVID-19 outbreak.","J Dermatolog Treat","Napolitano, Maddalena","Patruno, Cataldo","Ruggiero, Angelo","Nocerino, Mariateresa","Fabbrocini, Gabriella","32419563"],"journal":"J Dermatolog Treat","authors":["Napolitano, Maddalena","Patruno, Cataldo","Ruggiero, Angelo","Nocerino, Mariateresa","Fabbrocini, Gabriella"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32419563","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/09546634.2020.1771257","keywords":["covid-19","adult atopic dermatitis","dupilumab"],"topics":["Prevention"],"weight":1,"_version_":1667254896733192192,"score":136.42007},{"pmid":32447099,"title":"COVID-19, quarantine, and atopic dermatitis.","text":["COVID-19, quarantine, and atopic dermatitis.","Med Hypotheses","Patruno, Cataldo","Nistico, Steven Paul","Fabbrocini, Gabriella","Napolitano, Maddalena","32447099"],"journal":"Med Hypotheses","authors":["Patruno, Cataldo","Nistico, Steven Paul","Fabbrocini, Gabriella","Napolitano, Maddalena"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447099","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109852","keywords":["atopic dermatitis","covid-19","infection"],"topics":["Prevention"],"weight":1,"_version_":1667698385928323074,"score":130.55734},{"pmid":32405123,"pmcid":"PMC7217788","title":"Optimizing Care for Atopic Dermatitis Patients During COVID-19 Pandemic.","text":["Optimizing Care for Atopic Dermatitis Patients During COVID-19 Pandemic.","J Am Acad Dermatol","Shah, Monica","Sachdeva, Muskaan","Alavi, Afsaneh","Shi, Vivian Y","Hsiao, Jennifer L","32405123"],"journal":"J Am Acad Dermatol","authors":["Shah, Monica","Sachdeva, Muskaan","Alavi, Afsaneh","Shi, Vivian Y","Hsiao, Jennifer L"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405123","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jaad.2020.05.027","keywords":["covid-19","atopic dermatitis","coronavirus","emergency department","management","teledermatology","treatment"],"topics":["Prevention"],"weight":1,"_version_":1666802845264904192,"score":123.26425}]}